DaVita Inc. (NYSE:DVA) is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, DVA is expected to report 3Q20 income of $ 1.44 per share from revenue of $ 2937.32 million.
For the full year, analysts anticipate top line of $ 11597.40 million, while looking forward to income of $ 6.85 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 11,500.00 million ~ $ 11,700.00 million, where as bottomline are predicted in a range of $ 6.25 ~ $ 6.75 per share
Click Here For More Historical Outlooks Of DaVita Inc.
Previous Quarter Performance
DaVita Inc. revealed income for the second quarter of $ 1.95 per share, from the revenue of $ 2,880.00 million. The quarterly earnings swell 59.84 percent while revenues grew 1.31 percent compared with the same quarter last year.
Wall street analysts are predicting, DVA to report 2Q20 income of $ 1.30 per share from revenue of $ 2926.20 million. The bottom line results beat street analysts by $ 0.65 or 50.00 percent, at the same time, top line results fell short of analysts by $ 46.2 million or 1.58 percent.
Stock Performance
Shares of DaVita Inc. traded low $ -2.88 or -3.23 percent on Wednesday, reaching $ 86.27 with volume of 873.50 thousand shares. DaVita Inc. has traded high as $ 88.67 and has cracked $ 86.14 on the downward trend
According to the previous trading day, closing price of $ 86.27, representing a 53.31 % increase from the 52 week low of $ 58.15 and a 3.8 % decrease over the 52 week high of $ 92.67.
The company has a market capital of $ 10.52 billion and is part of the Healthcare sector and Medical Care industry.
Conference Call
DaVita Inc. will be hosting a conference call at 5:00 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.davita.com
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
